In 2011, brentuximab vedotin, an anti-CD30 mAb drug conjugate (ADC) to monomethyl auristatin E, was approved by the FDA in adults for relapsed or refractory Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL). Here, TNFRSF8 is linked to Hodgkins lymphoma.